Publications

• 1. Deane KD
  2. Donlin LT
  3. Ritchlin CT
  4. Kuhn KA
  Are There Disease Endotypes in Axial Spondyloarthritis and How Would We Define Them?; The Journal of rheumatology. 2024 Oct 24.
• 1. Mease PJ
  2. Merola JF
  3. Tanaka Y
  4. Gossec L
  5. McInnes IB
  6. Ritchlin CT
  7. Landewé RBM
  8. Asahina A
  9. Ink B
  10. Heinrichs A
  11. Bajracharya R
  12. Shende V
  13. Coarse J
  14. Coates LC
  Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies.; Rheumatology and therapy. 2024 Aug 31.
• 1. Bell RD
  2. Brendel M
  3. Konnaris MA
  4. Xiang J
  5. Otero M
  6. Fontana MA
  7. Bai Z
  8. Krenitsky DM
  9. Meednu N
  10. Rangel-Moreno J
  11. Scheel-Toellner D
  12. Carr H
  13. Nayar S
  14. McMurray J
  15. DiCarlo E
  16. Anolik JH
  17. Donlin LT
  18. Orange DE
  19. Kenney HM
  20. Schwarz EM
  21. Filer A
  22. Ivashkiv LB
  23. Wang F
  Automated multi-scale computational pathotyping (AMSCP) of inflamed synovial tissue.; Nature communications; Vol 15(1), pp. 7503. 2024 Aug 29.
• 1. Kenney HM
  2. Chen KL
  3. Schnur L
  4. Fox JI
  5. Wood RW
  6. Xing L
  7. Ritchlin CT
  8. Rahimi H
  9. Schwarz EM
  10. Awad HA
  High-throughput micro-CT analysis identifies sex-dependent biomarkers of erosive arthritis in TNF-Tg mice and differential response to anti-TNF therapy.; PloS one; Vol 19(7), pp. e0305623. 2024 Jul 05.
• 1. Ritchlin CT
  2. Rangel-Moreno J
  3. Martino D
  4. Isett B
  5. Paine A
  6. Bhattacharya S
  7. Fox J
  8. Meyer EM
  9. Bao R
  10. Bruno T
  11. Tausk F
  12. de la Luz Garcia-Hernandez M
  Psoriatic arthritis subtypes are phenocopied in humanized mice.; JCI insight; Vol 9(15). 2024 Jul 02.
• 1. Ritchlin CT
  2. Mease PJ
  3. Boehncke WH
  4. Tesser J
  5. Chakravarty SD
  6. Rampakakis E
  7. Shawi M
  8. Schiopu E
  9. Merola JF
  10. McInnes IB
  11. Deodhar A
  Durable control of psoriatic arthritis with guselkumab across domains and patient characteristics: post hoc analysis of a phase 3 study.; Clinical rheumatology. 2024 Jun 07.
• 1. Ogdie A
  2. Merola JF
  3. Mease PJ
  4. Ritchlin CT
  5. Scher JU
  6. Lafferty KP
  7. Chan D
  8. Chakravarty SD
  9. Langholff W
  10. Wang Y
  11. Choi O
  12. Krol Y
  13. Gottlieb AB
  Efficacy and safety of guselkumab in patients with active psoriatic arthritis who had inadequate efficacy and/or intolerance to one prior tumor necrosis factor inhibitor: study protocol for SOLSTICE, a phase 3B, multicenter, randomized, double-blind, placebo-controlled study.; BMC rheumatology; Vol 8(1), pp. 20. 2024 May 21.
• 1. Krueger JG
  2. Eyerich K
  3. Kuchroo VK
  4. Ritchlin CT
  5. Abreu MT
  6. Elloso MM
  7. Fourie A
  8. Fakharzadeh S
  9. Sherlock JP
  10. Yang YW
  11. Cua DJ
  12. McInnes IB
  IL-23 past, present, and future: a roadmap to advancing IL-23 science and therapy.; Frontiers in immunology; Vol 15, pp. 1331217. 2024 Apr 15.
• 1. Rahman P
  2. McInnes IB
  3. Deodhar A
  4. Schett G
  5. Mease PJ
  6. Shawi M
  7. Cua DJ
  8. Sherlock JP
  9. Kollmeier AP
  10. Xu XL
  11. Sheng S
  12. Ritchlin CT
  13. McGonagle D
  Association between enthesitis/dactylitis resolution and patient-reported outcomes in guselkumab-treated patients with psoriatic arthritis.; Clinical rheumatology. 2024 Mar 12.
• 1. Coates LC
  2. Landewé R
  3. McInnes IB
  4. Mease PJ
  5. Ritchlin CT
  6. Tanaka Y
  7. Asahina A
  8. Behrens F
  9. Gladman DD
  10. Gossec L
  11. Orbai AM
  12. Gottlieb AB
  13. Warren RB
  14. Ink B
  15. Bajracharya R
  16. Shende V
  17. Coarse J
  18. Merola JF
  Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL.; RMD open; Vol 10(1). 2024 Feb 22.
• 1. Chat VS
  2. Ellebrecht CT
  3. Kingston P
  4. Bell S
  5. Gondo G
  6. Cordoro KM
  7. Desai SR
  8. Duffin KC
  9. Feldman SR
  10. Garg A
  11. Gelfand JM
  12. Gladman D
  13. Green LJ
  14. Gudjonsson J
  15. Han G
  16. Hawkes JE
  17. Kircik L
  18. Koo J
  19. Langley R
  20. Lebwohl M
  21. Michael Lewitt G
  22. Liao W
  23. Martin G
  24. Orbai AM
  25. Reddy SM
  26. Richardson V
  27. Ritchlin CT
  28. Schwartzman S
  29. Siegel EL
  30. Van Voorhees AS
  31. Wallace EB
  32. Weinberg JM
  33. Winthrop KL
  34. Yamauchi P
  35. Armstrong AW
  Vaccination Recommendations for Adults Receiving Biologics and Oral Therapies for Psoriasis and Psoriatic Arthritis: Delphi Consensus from the Medical Board of the National Psoriasis Foundation.; Journal of the American Academy of Dermatology. 2024 Feb 06.
• 1. Furuya H
  2. Nguyen CT
  3. Chan T
  4. Marusina AI
  5. Merleev AA
  6. Garcia-Hernandez ML
  7. Hsieh SL
  8. Tsokos GC
  9. Ritchlin CT
  10. Tagkopoulos I
  11. Maverakis E
  12. Adamopoulos IE
  IL-23 induces CLEC5A+ IL-17A+ neutrophils and elicit skin inflammation associated with psoriatic arthritis.; Journal of autoimmunity; Vol 143, pp. 103167. 2024 Jan 31.
• 1. Ritchlin CT
  2. Coates LC
  3. McInnes IB
  4. Mease PJ
  5. Merola JF
  6. Tanaka Y
  7. Asahina A
  8. Gossec L
  9. Gottlieb AB
  10. Warren RB
  11. Ink B
  12. Bajracharya R
  13. Shende V
  14. Coarse J
  15. Landewé RB
  Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study.; Annals of the rheumatic diseases. 2023 Sep 11.
• 1. Kenney HM
  2. Rangel-Moreno J
  3. Peng Y
  4. Chen KL
  5. Bruno J
  6. Embong A
  7. Pritchett E
  8. Fox JI
  9. Becerril-Villanueva E
  10. Gamboa-Domínguez A
  11. Quataert S
  12. Muthukrishnan G
  13. Wood RW
  14. Korman BD
  15. Anolik JH
  16. Xing L
  17. Ritchlin CT
  18. Schwarz EM
  19. Wu CL
  Multi-omics analysis identifies IgG2b class-switching with ALCAM-CD6 co-stimulation in joint-draining lymph nodes during advanced inflammatory-erosive arthritis.; Frontiers in immunology; Vol 14, pp. 1237498. 2023 Aug 25.
• 1. Siebert S
  2. Sweet KM
  3. Ritchlin CT
  4. Hsia EC
  5. Kollmeier AP
  6. Xu XL
  7. Seridi L
  8. Song Q
  9. Gao S
  10. Chen W
  11. Miron M
  Guselkumab Modulates Differentially Expressed Genes in Blood of Patients With Psoriatic Arthritis: Results from Two Phase 3, Randomized, Placebo-Controlled Trials.; ACR open rheumatology. 2023 Aug 08.
• 1. Bawany F
  2. Ryan Wolff J
  3. Ritchlin CT
  4. Tausk F
  Home Phototherapy Improves Access to Dermatologic Care: A Novel Stakeholder Alliance to Facilitate Its Implementation.; Clinical, cosmetic and investigational dermatology; Vol 16, pp. 1175-1180. 2023 May 02.
• 1. Leung YY
  2. Kavanaugh A
  3. Ritchlin CT
  Expert Perspective: Management of the Psoriatic Arthritis Patient After Failure of One Anti-TNF inhibitor.; Arthritis & rheumatology (Hoboken, N.J.). 2023 Mar 16.
• 1. McGonagle D
  2. McInnes IB
  3. Deodhar A
  4. Schett G
  5. Shawi M
  6. Chakravarty SD
  7. Kollmeier AP
  8. Xu XL
  9. Sheng S
  10. Xu S
  11. Ritchlin CT
  12. Rahman P
  13. Mease PJ
  Guselkumab, a Selective Interleukin-23 p19 Subunit Inhibitor, Resolves Dactylitis in Patients With Active Psoriatic Arthritis: Pooled Results Through Week 52 From Two Phase 3 Studies.; ACR open rheumatology. 2023 Mar 07.
• 1. Kenney HM
  2. Dieudonne G
  3. Yee S
  4. Maki JH
  5. Wood RW
  6. Schwarz EM
  7. Ritchlin CT
  8. Rahimi H
  Near-Infrared Imaging of Indocyanine Green Identifies Novel Routes of Lymphatic Drainage from Metacarpophalangeal Joints in Healthy Human Hands.; Lymphatic research and biology. 2023 Feb 20.
• 1. Ritchlin CT
  2. Deodhar A
  3. Boehncke WH
  4. Soriano ER
  5. Kollmeier AP
  6. Xu XL
  7. Zazzetti F
  8. Shawi M
  9. Jiang Y
  10. Sheng S
  11. Helliwell PS
  Multidomain Efficacy and Safety of Guselkumab Through 1 Year in Patients With Active Psoriatic Arthritis With and Without Prior Tumor Necrosis Factor Inhibitor Experience: Analysis of the Phase 3, Randomized, Placebo-Controlled DISCOVER-1 Study.; ACR open rheumatology. 2023 Feb 10.
• 1. Kenney HM
  2. Wood RW
  3. Ramirez G
  4. Bell RD
  5. Chen KL
  6. Schnur L
  7. Rahimi H
  8. Korman BD
  9. Xing L
  10. Ritchlin CT
  11. Schwarz EM
  12. Cole CL
  Implementation of automated behavior metrics to evaluate voluntary wheel running effects on inflammatory-erosive arthritis and interstitial lung disease in TNF-Tg mice.; Arthritis research & therapy; Vol 25(1), pp. 17. 2023 Feb 02.
• 1. Kenney HM
  2. Peng Y
  3. de Mesy Bentley KL
  4. Xing L
  5. Ritchlin CT
  6. Schwarz EM
  The Enigmas of Lymphatic Muscle Cells: Where Do They Come From, How Are They Maintained, and Can They Regenerate?; Current rheumatology reviews. 2023 Jan 27.
• 1. Peng Y
  2. Kenney HM
  3. de Mesy Bentley KL
  4. Xing L
  5. Ritchlin CT
  6. Schwarz EM
  Distinct mast cell subpopulations within and around lymphatic vessels regulate lymph flow and progression of inflammatory-erosive arthritis in TNF-transgenic mice.; Frontiers in immunology; Vol 14, pp. 1275871. 2023 Jan 14.
• 1. Ritchlin CT
  2. Coates LC
  3. Mease PJ
  4. van der Heijde D
  5. Song J
  6. Jiang Y
  7. Shawi M
  8. Kollmeier AP
  9. Rahman P
  The effect of guselkumab on inhibiting radiographic progression in patients with active psoriatic arthritis: study protocol for APEX, a Phase 3b, multicenter, randomized, double-blind, placebo-controlled trial.; Trials; Vol 24(1), pp. 22. 2023 Jan 10.
• 1. Kenney HM
  2. Peng Y
  3. Bell RD
  4. Wood RW
  5. Xing L
  6. Ritchlin CT
  7. Schwarz EM
  Persistent popliteal lymphatic muscle cell coverage defects despite amelioration of arthritis and recovery of popliteal lymphatic vessel function in TNF-Tg mice following anti-TNF therapy.; Scientific reports; Vol 12(1), pp. 12751. 2022 Jul 26.
• 1. Coates LC
  2. McInnes IB
  3. Merola JF
  4. Warren RB
  5. Kavanaugh A
  6. Gottlieb AB
  7. Gossec L
  8. Assudani D
  9. Bajracharya R
  10. Coarse J
  11. Ink B
  12. Ritchlin CT
  Safety and Efficacy of Bimekizumab in Patients with Active Psoriatic Arthritis: 3-Year Results from a Phase 2b Randomized Controlled Trial and its Open-Label Extension Study.; Arthritis & rheumatology (Hoboken, N.J.). 2022 Jul 13.
• 1. Orbai AM
  2. Coates LC
  3. Deodhar A
  4. Helliwell PS
  5. Ritchlin CT
  6. Leibowitz E
  7. Kollmeier AP
  8. Hsia EC
  9. Xu XL
  10. Sheng S
  11. Jiang Y
  12. Liu Y
  13. Han C
  Meaningful Improvement in General Health Outcomes with Guselkumab Treatment for Psoriatic Arthritis: Patient-Reported Outcomes Measurement Information System-29 Results from a Phase 3 Study.; The patient. 2022 Jun 30.
• 1. Coates LC
  2. Ritchlin CT
  3. Gossec L
  4. Helliwell PS
  5. Rahman P
  6. Kollmeier AP
  7. Xu XL
  8. Shawi M
  9. Karyekar CS
  10. Contré C
  11. Noël W
  12. Sheng S
  13. Wang Y
  14. Xu S
  15. Mease PJ
  Guselkumab provides sustained domain-specific and comprehensive efficacy using composite indices in patients with active psoriatic arthritis.; Rheumatology (Oxford, England). 2022 Jun 29.
• 1. Stober C
  2. McInnes IB
  3. Raychaudhuri S
  4. Mease PJ
  5. Pennington SR
  6. Scher JU
  7. Chandran V
  8. Armstrong AW
  9. de Wit M
  10. Cauli A
  11. Jadon DR
  12. Löve TJ
  13. Ogdie A
  14. O'Sullivan D
  15. van Mens LJJ
  16. Ritchlin CT
  17. FitzGerald O
  Proceedings of the 2021 GRAPPA-Collaborative Research Network (CRN) Meeting.; The Journal of rheumatology. 2022 Apr 01.
• 1. Rangel-Moreno J
  2. Garcia-Hernandez ML
  3. Owen T
  4. Barnard J
  5. Becerril-Villanueva E
  6. Kashyap T
  7. Argueta C
  8. Gamboa-Dominguez A
  9. Tamir S
  10. Landesman Y
  11. Goldman BI
  12. Ritchlin CT
  13. Anolik JH
  Small molecule inhibitors of nuclear export ameliorate lupus by modulating plasma cell generation and survival.; Arthritis & rheumatology (Hoboken, N.J.). 2022 Mar 25.
• 1. Kenney HM
  2. Wu CL
  3. Loiselle AE
  4. Xing L
  5. Ritchlin CT
  6. Schwarz EM
  Single-cell transcriptomics of popliteal lymphatic vessels and peripheral veins reveals altered lymphatic muscle and immune cell populations in the TNF-Tg arthritis model.; Arthritis research & therapy; Vol 24(1). 2022 Mar 07.
• 1. Ritchlin CT
  2. Mease PJ
  3. Boehncke WH
  4. Tesser J
  5. Schiopu E
  6. Chakravarty SD
  7. Kollmeier AP
  8. Xu XL
  9. Shawi M
  10. Jiang Y
  11. Sheng S
  12. Wang Y
  13. Xu S
  14. Merola JF
  15. McInnes IB
  16. Deodhar A
  Sustained and improved guselkumab response in patients with active psoriatic arthritis regardless of baseline demographic and disease characteristics: pooled results through week 52 of two phase III, randomised, placebo-controlled studies.; RMD open; Vol 8(1). 2022 Mar.
• 1. Garcia-Hernandez ML
  2. Rangel-Moreno J
  3. Garcia-Castaneda M
  4. Kenney HM
  5. Paine A
  6. Thullen M
  7. Anandarajah AP
  8. Schwarz EM
  9. Dirksen RT
  10. Ritchlin CT
  Dendritic cell-specific transmembrane protein is required for synovitis and bone resorption in inflammatory arthritis.; Frontiers in immunology; Vol 13, pp. 1026574. 2022 Jan 07.
• 1. McInnes IB
  2. Asahina A
  3. Coates LC
  4. Landewé R
  5. Merola JF
  6. Ritchlin CT
  7. Tanaka Y
  8. Gossec L
  9. Gottlieb AB
  10. Warren RB
  11. Ink B
  12. Assudani D
  13. Bajracharya R
  14. Shende V
  15. Coarse J
  16. Mease PJ
  Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL).; Lancet (London, England). 2022 Jan 05.
• 1. Merola JF
  2. Landewé R
  3. McInnes IB
  4. Mease PJ
  5. Ritchlin CT
  6. Tanaka Y
  7. Asahina A
  8. Behrens F
  9. Gladman DD
  10. Gossec L
  11. Gottlieb AB
  12. Thaçi D
  13. Warren RB
  14. Ink B
  15. Assudani D
  16. Bajracharya R
  17. Shende V
  18. Coarse J
  19. Coates LC
  Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE).; Lancet (London, England). 2022 Jan 05.
• 1. Gondo GC
  2. Noe MH
  3. Bell SJ
  4. Ritchlin CT
  Likelihood of COVID-19 Vaccination Among Individuals Living With Psoriatic Disease: Results From a Large Real-World Survey.; Journal of psoriasis and psoriatic arthritis; Vol 7(1), pp. 17-23. 2021 Dec 10.
• 1. Pournara E
  2. Kormaksson M
  3. Nash P
  4. Ritchlin CT
  5. Kirkham BW
  6. Ligozio G
  7. Pricop L
  8. Ogdie A
  9. Coates LC
  10. Schett G
  11. McInnes IB
  Clinically relevant patient clusters identified by machine learning from the clinical development programme of secukinumab in psoriatic arthritis.; RMD open; Vol 7(3). 2021 Nov.
• 1. Kolbinger F
  2. Di Padova F
  3. Deodhar A
  4. Hawkes JE
  5. Huppertz C
  6. Kuiper T
  7. McInnes IB
  8. Ritchlin CT
  9. Rosmarin D
  10. Schett G
  11. Carballido JM
  12. Häusermann P
  13. Calonder C
  14. Vogel B
  15. Rondeau JM
  16. Bruin G
  Secukinumab for the treatment of psoriasis, psoriatic arthritis, and axial spondyloarthritis: Physical and pharmacological properties underlie the observed clinical efficacy and safety.; Pharmacology & therapeutics. 2021 Jun 22.
• 1. Ritchlin CT
  2. Armstrong A
  3. Johnsson H
  4. Mulder MLM
  GRAPPA Trainee Symposium 2020: A Summary of Oral and Poster Presentations.; The Journal of rheumatology. Supplement; Vol 97. 2021 Jun.
• 1. Stober C
  2. Jadon DR
  3. Armstrong AW
  4. Chandran V
  5. de Wit M
  6. Helliwell PS
  7. Mease PJ
  8. Ogdie A
  9. O'Sullivan D
  10. Pennington SR
  11. Löve T
  12. Cauli A
  13. van Mens L
  14. Waxman R
  15. Scher JU
  16. Barton A
  17. Ritchlin CT
  18. FitzGerald O
  Proceedings of the 2020 GRAPPA Collaborative Research Network (CRN) Meeting.; The Journal of rheumatology. Supplement; Vol 97. 2021 Jun.
• 1. Ogdie A
  2. Ritchlin CT
  Overview of the Grant Writing Workshop From the GRAPPA 2020 Annual Meeting.; The Journal of rheumatology. Supplement; Vol 97. 2021 Jun.
• 1. Rahman P
  2. Ritchlin CT
  3. Helliwell PS
  4. Boehncke WH
  5. Mease PJ
  6. Gottlieb AB
  7. Kafka S
  8. Kollmeier AP
  9. Hsia EC
  10. Xu XL
  11. Shawi M
  12. Sheng S
  13. Agarwal P
  14. Zhou B
  15. Ramachandran P
  16. Zhuang Y
  17. McInnes IB
  Pooled Safety Results Through One Year of Two Phase-3 Trials of Guselkumab in Patients with Psoriatic Arthritis.; The Journal of rheumatology. 2021 May 01.
• 1. McGonagle D
  2. McInnes IB
  3. Deodhar A
  4. Schett G
  5. Shawi M
  6. Kafka S
  7. Karyekar CS
  8. Kollmeier AP
  9. Hsia EC
  10. Xu XL
  11. Sheng S
  12. Agarwal P
  13. Zhou B
  14. Ritchlin CT
  15. Rahman P
  16. Mease PJ
  Resolution of Enthesitis by Guselkumab and Relationships to Disease Burden: 1-Year Results of Two Phase-3 Psoriatic Arthritis Studies.; Rheumatology (Oxford, England). 2021 Apr 06.
• 1. Ogdie A
  2. Ritchlin CT
  Overview of the Grant Writing Workshop From the GRAPPA 2020 Annual Meeting.; The Journal of rheumatology. 2021 Feb 15.
• 1. Stober C
  2. Jadon DR
  3. Armstrong AW
  4. Chandran V
  5. de Wit M
  6. Helliwell PS
  7. Mease P
  8. Ogdie A
  9. O'Sullivan D
  10. Pennington SR
  11. Löve T
  12. Cauli A
  13. van Mens L
  14. Waxman R
  15. Scher JU
  16. Barton A
  17. Ritchlin CT
  18. FitzGerald O
  Proceedings of the 2020 GRAPPA Collaborative Research Network (CRN) Meeting.; The Journal of rheumatology. 2021 Feb 15.
• 1. Ritchlin CT
  2. Helliwell PS
  3. Boehncke WH
  4. Soriano ER
  5. Hsia EC
  6. Kollmeier AP
  7. Chakravarty SD
  8. Zazzetti F
  9. Subramanian RA
  10. Xu XL
  11. Zuraw QC
  12. Sheng S
  13. Jiang Y
  14. Agarwal P
  15. Zhou B
  16. Zhuang Y
  17. Shawi M
  18. Karyekar CS
  19. Deodhar A
  Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study of patients who were biologic-naïve or TNFα inhibitor-experienced.; RMD open; Vol 7(1). 2021 Feb.
• 1. Gelfand JM
  2. Armstrong AW
  3. Bell S
  4. Anesi GL
  5. Blauvelt A
  6. Calabrese C
  7. Dommasch ED
  8. Feldman SR
  9. Gladman D
  10. Kircik L
  11. Lebwohl M
  12. Lo Re V
  13. Martin G
  14. Merola JF
  15. Scher JU
  16. Schwartzman S
  17. Treat JR
  18. Van Voorhees AS
  19. Ellebrecht CT
  20. Fenner J
  21. Ocon A
  22. Syed MN
  23. Weinstein EJ
  24. Gondo G
  25. Heydon S
  26. Koons S
  27. Ritchlin CT
  National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2-Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments.; Journal of the American Academy of Dermatology. 2021 Jan 07.
• 1. Scallan JP
  2. Bouta EM
  3. Rahimi H
  4. Kenney HM
  5. Ritchlin CT
  6. Davis MJ
  7. Schwarz EM
  Ex vivo Demonstration of Functional Deficiencies in Popliteal Lymphatic Vessels From TNF-Transgenic Mice With Inflammatory Arthritis.; Frontiers in physiology; Vol 12. 2021.
• 1. Kenney HM
  2. Bell RD
  3. Masters EA
  4. Xing L
  5. Ritchlin CT
  6. Schwarz EM
  Lineage tracing reveals evidence of a popliteal lymphatic muscle progenitor cell that is distinct from skeletal and vascular muscle progenitors.; Scientific reports; Vol 10(1). 2020 Oct 22.
• 1. Ritchlin CT
  2. Giles JT
  3. Ogdie A
  4. Gomez-Reino JJ
  5. Helliwell P
  6. Young P
  7. Wang C
  8. Wu J
  9. Romero AB
  10. Woolcott J
  11. Stockert L
  Tofacitinib in Patients With Psoriatic Arthritis and Metabolic Syndrome: A Post hoc Analysis of Phase 3 Studies.; ACR open rheumatology; Vol 2(10). 2020 Oct.

View All Publications